Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06499857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Study acronym: SEMINAL-AF
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Minor Re-verified, no change to tracked fieldsv7
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2025 to Apr 14, 2025
    • Site details revised at 2 of 2 sites
    v6
  3. Notable Start date: Mar 2025 to Jun 2025v5
  4. Minor Start date: Jan 2025 to Mar 2025v4
  5. Minor Secondary endpoints: details revised at 1 of 16 entriesv3
  6. Notable Start date: Jul 2024 to Jan 2025v2
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
8,786 trials monitored
See 412 trials at risk
3,874 trials monitored
See 152 trials at risk
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Trial Details
NCT Number NCT06499857
Lead Sponsor University of Chicago
Conditions
(from sponsor)
Overweight or Obesity, Atrial Fibrillation
Related terms Atrial Fibrillation, Obesity, Overweight
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov